Dabrafenib/Trametinib Effective in Mutated Biliary Tract Cancer

Patients with biliary tract cancer often experience disease relapse after gemcitabine-based chemotherapy, representing an area of need in this patient population. In 5% of biliary tract tumors, a mutation in the BRAF gene is found. Dabrafenib in combination with trametinib has been shown to be an effective treatment option for patients with BRAFV600E – mutated cancers, particularly those with biliary tract cancer, according to a recent study, results of which were published in The Lancet Oncolog...
Continue reading

DNA Damage Repair Inhibitors Fight Small Cell Lung Cancer

Patients with small cell lung cancer (SCLC) often do not respond to immune checkpoint blockade therapy alone. However, researchers at the University of Texas MD Anderson Cancer Center now report that a combination of immune checkpoint blockade therapy and targeted therapies blocking DNA damage repair significantly shrinks tumors in mouse models of SCLC. "While the use of immunotherapy has revolutionized the way we treat lung cancer, we find that small cell lung cancers can escape the immune syst...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.